Neovacs will partner with 3P Biopharmaceuticals to manufacture interferon alpha following its purchase of technology from AMEGABIOTECH. Read More »

Eli Lilly and Co.'s EXPEDITION3 clinical study involving solanezumab failed to meet its primary goal in treating Alzheimer’s. Read More »

Baxter International recently presented its research on extracorporeal blood purification and its role in the removing of molecules associated with inflammation at the American Society of Nephrology’s annual Kidney Week. Read More »

Novo Nordisk's Changing Diabetes in Children program has received a four-year extension to provide access to diabetes care and free insulin to children in developing countries who have Type 1 diabetes. Read More »

Merck has released new data involving KEYTRUDA, Merck’s anti-PD-1 therapy designed for the treatment of a number of blood cancers, and its investigational use. Read More »

Mallinckrodt's Phase 2 clinical study involving H.P. Acthar Gel to evaluate the effectiveness of the medication on patients who have Amytropic Lateral Sclerosis will begin in 2017. Read More »

CVS Pharmacy's Black Friday sales event will give its ExtraCare members the opportunity to save. Read More »

Arrowhead Pharmaceuticals has closed the license and collaboration agreement with Amgen regarding the RNAi ARC-LPA program. Read More »

Intarcia Therapeutics has submitted its New Drug Application (NDA) for ITCA 650 to the U.S. Food and Drug Administration. Read More »

Kmart Pharmacy has added Medicare Part D and its members can now use Kmart Pharmacy for their pharmaceutical needs in 2017 as their preferred provider. Read More »

Pfizer's executive vice president and president of global supply Anthony Maddaluna is retiring after 41 years with the company. Read More »

The Data Safety Monitoring Board has awarded Onxeo S.A. with its ninth unanimous recommendation. Read More »

Agios Pharmaceuticals recently presented the first data from its Phase 1 AG-120 study dose expansion cohorts at the Society for Neuro-Oncology annual meeting. Read More »

The Academy of Managed Care Pharmacy recently hosted a national health care forum about value and outcomes in oncology where the key topics of conversation revolved around the fast-growing innovations in oncology and how complex cancer treatments have become. Read More »

Novocure's long-term data results of its Phase 3 EF-14 trial involving Optune combined with temozolomide are consistent with the results from the interim analysis of the data. Read More »

Celgene Corp. has purchased Triphase Accelerator Corp.'s assets regarding its proteasome inhibitor, marizomib, which is being developed for the treatment of glioblastoma and relapsed and/or refractory multiple myeloma. Read More »

Merck KGaA's businesses in Massachusetts have been ranked among the “Top Places to Work” by The Boston Globe. Read More »

Bayer has formed a Phase 3 clinical trial that will assess the safety and effectiveness of Nifurtimox, a formulation designed to treat children of all ages that have been diagnosed with Chagas disease. Read More »

CSL Behring's Phase 2b clinical trial involving AEGIS-I has turned in positive results. Read More »

Amgen's addition of RepathaA (evolocumab) to optimized statin therapy has resulted in a noteworthy statistical decrease of atherosclerosis in patients who have coronary artery disease. Read More »